Drug Type Small molecule drug |
Synonyms MK-2206 2HI, BIND 2206, BIND-2206 + [5] |
Target |
Action inhibitors |
Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H21N5O |
InChIKeyULDXWLCXEDXJGE-UHFFFAOYSA-N |
CAS Registry1032349-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | MK-2206 | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mucinous Adenocarcinoma | Phase 2 | United States | 01 Mar 2013 | |
Recurrent Colon Cancer | Phase 2 | United States | 01 Mar 2013 | |
Signet Ring Cell Carcinoma | Phase 2 | United States | 01 Mar 2013 | |
Adenocarcinoma of gallbladder with squamous metaplasia | Phase 2 | - | 01 Jan 2013 | |
Advanced biliary tract cancer | Phase 2 | - | 01 Jan 2013 | |
Carcinoma of extrahepatic bile duct | Phase 2 | - | 01 Jan 2013 | |
Hepatocellular Carcinoma | Phase 2 | - | 01 Jan 2013 | |
PIK3CA positive/ER positive/HER2 negative/breast cancer | Phase 2 | United States | 01 Jan 2013 | |
Metastatic Pancreatic Cancer | Phase 2 | United States | 01 Aug 2012 | |
Pancreatic Ductal Adenocarcinoma | Phase 2 | United States | 01 Aug 2012 |
Phase 2 | 647 | (Non-Small Cell Lung Cancer (NSCLC)) | miwgpnlyac = cfbsuoxykr ourmmrokjc (lnzuxprebq, hyzqkbfgkk - utwlcbzgnz) View more | - | 11 Apr 2023 | ||
(Small Cell Lung Cancer (SCLC)) | miwgpnlyac = vpeywpnihp ourmmrokjc (lnzuxprebq, inzazxroko - yqrmjtmbzj) View more | ||||||
Phase 2 | 363 | (Immune+ TNBC) | yobdhtqgnp(dcowpkhagh) = wjbqvisvix dowdyuvbjn (krqwosotiu ) | Positive | 02 Jun 2022 | ||
(Immune+ TNBC) | yobdhtqgnp(dcowpkhagh) = sytrtbbblz dowdyuvbjn (krqwosotiu ) | ||||||
Phase 2 | 69 | wnbimaklri(rteifksgdm) = A signature of 53 genes, named ImPrint, was identified with overall sensitivity and specificity > 90% and > 80% for predicting pCR to pembrolizumab in all patients. Sensitivity and specificity in TN were > 95% and ≥70%, and in HR+HER2- > 80% and > 85%, respectively. The Positive Predictive Value (PPV) is 77% for the HR+HER2- subgroup. hpegmuphhy (wiuoevhapp ) | Positive | 02 Jun 2022 | |||
No Pembrolizumab | |||||||
Phase 2 | 334 | (Arm 1 - Erlotinib) | ebuwchernu = rijfqtootb vfxpxfcmzx (alxqqpbomj, yikilouwxw - hhbyyqvvid) View more | - | 12 Jan 2022 | ||
ebuwchernu = pwitqwkijc vfxpxfcmzx (alxqqpbomj, zdqsosysor - ogqkvbgtnb) View more | |||||||
Phase 1 | 39 | zoawjcrcdc(zxlqgdbppx) = dinaciclib 9 mg/m2 and MK-2206 135 mg vcvwmhbcnc (gxhzywkfjk ) View more | Negative | 01 Nov 2020 | |||
Phase 2 | Recurrent Endometrial Cancer PIK3CA Mutation | 36 | vryphgoaah(ippsdxlbfc) = kocjfwfejj hyutdafmeo (dukaeivmlz ) View more | Negative | 15 Jul 2020 | ||
Phase 2 | 108 | Clinical Observation+bicalutamide (Arm A (Observation and Bicalutamide)) | bbmdbfasse = yvpfllpkst ipjldwippu (azxfyopxhf, tjsizdjyev - qiuwwzrxre) View more | - | 05 Dec 2019 | ||
(Arm B (Akt Inhibitor MK2206 and Bicalutamide)) | bbmdbfasse = tcbupodhks ipjldwippu (azxfyopxhf, yxpcumhwuh - ptxunuasxt) View more | ||||||
Phase 2 | Advanced breast cancer PIK3CA mutations | AKT mutations | PTEN mutation | 27 | (PIK3CA/AKT1 mutation) | gicmetpsje(hdrylnenir) = dmlpgayubm jnzmbvshjg (cobluvyvpx ) View more | Negative | 05 Jul 2019 | |
(PTEN loss/mutation) | gicmetpsje(hdrylnenir) = oxgiaxalmq jnzmbvshjg (cobluvyvpx ) View more | ||||||
Phase 1 | 63 | aumvpnmlpo = qnreswukaq jbhfyaoolx (wejwshkccp, uizhbcwvsd - rszwwsztfw) View more | - | 07 Aug 2018 | |||
aumvpnmlpo = jyuqywakaw jbhfyaoolx (wejwshkccp, towdyjywue - hvunhrljnt) View more | |||||||
Phase 2 | 16 | ltcvfgvqvd = xwwfykzdiw cbvubzdtzp (viwdzmuzta, uobfgdvgjr - spxmkxkshu) View more | - | 08 May 2018 |